Do PET-positive supradiaphragmatic lymph nodes predict overall survival or the success of primary surgery in patients with advanced ovarian cancer?

Autor: Braun C; Department of Gynecology and Gynecologic Oncology, Luzerner Kantonsspital, Lucerne, Switzerland. Electronic address: christian.braun@luks.ch., Grünig H; Department of Nuclear Medicine, Luzerner Kantonsspital, Lucerne, Switzerland., Peikert J; Department of Gynecology and Gynecologic Oncology, Luzerner Kantonsspital, Lucerne, Switzerland., Strobel K; Department of Nuclear Medicine, Luzerner Kantonsspital, Lucerne, Switzerland., Christmann-Schmid C; Department of Gynecology and Gynecologic Oncology, Luzerner Kantonsspital, Lucerne, Switzerland., Brambs C; Department of Gynecology and Gynecologic Oncology, Luzerner Kantonsspital, Lucerne, Switzerland.
Jazyk: angličtina
Zdroj: European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2024 May; Vol. 296, pp. 13-19. Date of Electronic Publication: 2024 Feb 21.
DOI: 10.1016/j.ejogrb.2024.02.028
Abstrakt: Objectives: Compared to conventional computed tomography (CT), fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) detects higher rates of lymph node and distant metastases in patients with ovarian cancer. However, FDG-PET/CT is not routinely performed during preoperative work-up. Therefore, we investigated the prognostic value of preoperative FDG-PET/CT in advanced epithelial ovarian cancer (EOC) and its predictive value for surgical resection in patients with no residual disease. The potential significance of PET-positive supradiaphragmatic lymph nodes (SDLNs) for these parameters was evaluated.
Methods: All patients with FIGO IIA-IVB EOC diagnosed between March 2014 and January 2021 at our certified gynaecological cancer centre, who underwent FDG PET/CT before primary surgery were retrospectively included.
Results: Fifty-three consecutive patients were included in the study. Eighteen (34 %) patients had PET-positive SDLNs. We could not demonstrate a significant correlation between PET-positive SDLNs and median overall survival (OS; SDLN-positive: 58.76 months, SDLN-negative: 60.76 months; p = 0.137) or intra- or perioperative outcomes.
Conclusions: FDG PET/CT has a higher detection rate for SDLNs in patients with ovarian cancer than CT has, as described in the literature. Moreover, PET-positive SDLNs failed to predict intraoperative outcomes or overall survival.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: